CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Exploring new treatment avenues has become crucial as mental health challenges such as depression and PTSD continue impacting a significant number of individuals globally. Traditional therapies might not work for everyone,

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of research suggesting it can be especially effective against types

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year than those who reported no past-year drug use.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray,

It has been claimed that former adult star Emily Willis, 25, is now "permanently disabled" and in a semi-conscious state after going to rehab for a "ketamine addiction"

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental health conditions. However, they may cover the FDA-approved nasal spray, Spravato, which contains a derivative of ketamine called esketamine.